Literature DB >> 7711425

Lecithin-cholesterol acryltransferase activity in patients with coronary artery disease examined by coronary angiography.

N Solajić-Bozicević1, A Stavljenić-Rukavina, M Sesto.   

Abstract

This study grew out of observations of certain lecithin:cholesterol acyltransferase (LCAT) abnormalities in patients with atherosclerosis. We studied the interrelationships among LCAT, and total cholesterol, free and esterified cholesterol, cholesterol in individual lipoprotein fractions, triglycerides, phospholipids, free fatty acids, L-lactates in 90 angiographically examined patients with coronary artery disease and 30 control subjects without clinical manifestations of coronary artery disease. Results of the study showed LCAT activity to be significantly decreased (P < 0.05) in patients with single-, double-, or triple-vessel disease than in disease-free subjects. LCAT was also found to follow the stage of coronary artery disease in angiographically examined patients. Decreased LCAT activity was accompanied by lower high-density lipoprotein cholesterol, elevated ratio of unesterified to esterified cholesterol, and increased levels of L-lactates, free fatty acids, and low-density lipoprotein cholesterol. Total cholesterol and triglycerides were within or slightly above the normal limits. The results show LCAT to be a significantly better indicator of the risk of coronary artery disease than either total cholesterol or triglycerides.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7711425     DOI: 10.1007/bf00577734

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  23 in total

1.  Isolation, properties, and mechanism of in vitro action of lecithin: cholesterol acyltransferase from human plasma.

Authors:  J Chung; D A Abano; G M Fless; A M Scanu
Journal:  J Biol Chem       Date:  1979-08-10       Impact factor: 5.157

2.  Lecithin: cholesterol acyltransferase of human plasma. Role of chylomicrons, very low, and high density lipoproteins in the reaction.

Authors:  Y L Marcel; C Vezina
Journal:  J Biol Chem       Date:  1973-12-10       Impact factor: 5.157

3.  Serum cholesterol esterification in species resistant and susceptible to atherosclerosis.

Authors:  A G Lacko; H L Rutenberg; L A Soloff
Journal:  Atherosclerosis       Date:  1974 Mar-Apr       Impact factor: 5.162

4.  Quantitative determination of serum triglycerides by the use of enzymes.

Authors:  G Bucolo; H David
Journal:  Clin Chem       Date:  1973-05       Impact factor: 8.327

5.  Risk factors for ischaemic heart disease in men and women. Results of the 19-year follow-up of the Stockholm Prospective Study.

Authors:  L A Carlson; L E Böttiger
Journal:  Acta Med Scand       Date:  1985

6.  Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction.

Authors:  J L Goldstein; W R Hazzard; H G Schrott; E L Bierman; A G Motulsky
Journal:  J Clin Invest       Date:  1973-07       Impact factor: 14.808

7.  Strategies for the prevention of coronary heart disease: a policy statement of the European Atherosclerosis Society.

Authors: 
Journal:  Eur Heart J       Date:  1987-01       Impact factor: 29.983

8.  Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure.

Authors:  L I Gidez; G J Miller; M Burstein; S Slagle; H A Eder
Journal:  J Lipid Res       Date:  1982-11       Impact factor: 5.922

9.  Serum triglycerides are a risk factor for myocardial infarction but not for angina pectoris. Results from a 10-year follow-up of Uppsala primary preventive study.

Authors:  H Aberg; H Lithell; I Selinus; H Hedstrand
Journal:  Atherosclerosis       Date:  1985-01       Impact factor: 5.162

10.  Anatomical progression of coronary artery disease in humans as seen by prospective, repeated, quantitated coronary angiography. Relation to clinical events and risk factors. The INTACT Study Group.

Authors:  P R Lichtlen; P Nikutta; S Jost; J Deckers; B Wiese; W Rafflenbeul
Journal:  Circulation       Date:  1992-09       Impact factor: 29.690

View more
  9 in total

1.  Influence of apolipoprotein A-I domain structure on macrophage reverse cholesterol transport in mice.

Authors:  Eric T Alexander; Charulatha Vedhachalam; Sandhya Sankaranarayanan; Margarita de la Llera-Moya; George H Rothblat; Daniel J Rader; Michael C Phillips
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

2.  Association of lecithin-cholesterol acyltransferase activity measured as a serum cholesterol esterification rate and low-density lipoprotein heterogeneity with cardiovascular risk: a cross-sectional study.

Authors:  Shigemasa Tani; Atsuhiko Takahashi; Ken Nagao; Atsushi Hirayama
Journal:  Heart Vessels       Date:  2015-04-19       Impact factor: 2.037

3.  Safety and Tolerability of ACP-501, a Recombinant Human Lecithin:Cholesterol Acyltransferase, in a Phase 1 Single-Dose Escalation Study.

Authors:  Robert D Shamburek; Rebecca Bakker-Arkema; Alexandra M Shamburek; Lita A Freeman; Marcelo J Amar; Bruce Auerbach; Brian R Krause; Reynold Homan; Steve J Adelman; Heidi L Collins; Maureen Sampson; Anna Wolska; Alan T Remaley
Journal:  Circ Res       Date:  2015-12-01       Impact factor: 17.367

4.  Plasma lecithin:cholesterol acyltransferase and carotid intima-media thickness in European individuals at high cardiovascular risk.

Authors:  Laura Calabresi; Damiano Baldassarre; Sara Simonelli; Monica Gomaraschi; Mauro Amato; Samuela Castelnuovo; Beatrice Frigerio; Alessio Ravani; Daniela Sansaro; Jussi Kauhanen; Rainer Rauramaa; Ulf de Faire; Anders Hamsten; Andries J Smit; Elmo Mannarino; Steve E Humphries; Philippe Giral; Fabrizio Veglia; Cesare R Sirtori; Guido Franceschini; Elena Tremoli
Journal:  J Lipid Res       Date:  2011-05-19       Impact factor: 5.922

5.  Plasma levels of lecithin:cholesterol acyltransferase and risk of future coronary artery disease in apparently healthy men and women: a prospective case-control analysis nested in the EPIC-Norfolk population study.

Authors:  A G Holleboom; J A Kuivenhoven; M Vergeer; G K Hovingh; J N van Miert; N J Wareham; J J P Kastelein; K-T Khaw; S M Boekholdt
Journal:  J Lipid Res       Date:  2009-08-11       Impact factor: 5.922

Review 6.  Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis?

Authors:  Sandra Kunnen; Miranda Van Eck
Journal:  J Lipid Res       Date:  2012-05-07       Impact factor: 5.922

Review 7.  Lecithin: cholesterol acyltransferase--from biochemistry to role in cardiovascular disease.

Authors:  Xavier Rousset; Boris Vaisman; Marcelo Amar; Amar A Sethi; Alan T Remaley
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2009-04       Impact factor: 3.243

Review 8.  Very low levels of HDL cholesterol and atherosclerosis, a variable relationship--a review of LCAT deficiency.

Authors:  Julia Savel; Marianne Lafitte; Yann Pucheu; Vincent Pradeau; Antoine Tabarin; Thierry Couffinhal
Journal:  Vasc Health Risk Manag       Date:  2012-06-05

9.  An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration.

Authors:  Xun Chen; Charlotte Burton; Xuelei Song; Lesley McNamara; Annunziata Langella; Simona Cianetti; Ching H Chang; Jun Wang
Journal:  Int J Biol Sci       Date:  2009-07-28       Impact factor: 6.580

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.